Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S.
Patent Will Specifically Cover Prophylactic and Post-Exposure Use of NasoShield in the U.S.
Patents with Similar Protection Already Issued in
Anthrax vaccines can be used as General Use Prophylactics (GUP) to establish immunity to anthrax disease prior to exposure to the pathogen, or as a Post-Exposure Prophylactic (PEP) for use with antibiotic therapy following exposure to the pathogen. The ‘570 patent covers NasoShield in both the GUP and PEP setting.
“We continue to protect our technology through strategic intellectual property achievements and this Notice of Allowance is an important addition to our IP portfolio,” said
Altimmune’s NasoShield anthrax vaccine candidate is being developed as the ultimate anthrax vaccine. NasoShield is based on the Company’s RespirVec technology to provide protection following a single intranasal administration as opposed to multiple injections. Based on head-to-head results from studies performed in gold-standard preclinical models, NasoShield provided more rapid and persistent protection when compared to the currently approved anthrax vaccine, both potential key advantages for presumed use in a bioterrorism emergency.
The Company’s anthrax vaccine candidates are being developed with support from the
About
Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any product or drug candidates, and the Company’s leadership are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: realizing the benefits of the merger between Altimmune, Inc. and PharmAthene, Inc.; clinical trials and the commercialization of proposed product candidates (such as marketing, regulatory, product liability, supply, competition, dependence on third parties and other risks); the regulatory approval process; dependence on intellectual property; the Company’s BARDA contract and other government programs, reimbursement and regulation; and the lack of financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Form 10-K filed March 14, 2017, Forms 10-Q filed
Altimmune Contacts
President and CEO
Phone: 240-654-1450
Email: enright@altimmune.com
LifeSci Advisors, LLC
617-775-5956
arr@lifesciadvisors.com
Source: Altimmune, Inc.